SCHEMBL12413347

SCHEMBL12413347

CCCCc1oc2cc(C)ccc2c(=O)c1-c1ccc(OC(C)=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.56
FPR1 P21462 9/20 0.52
KDM4E B2RXH2 4/20 0.52
MAPT P10636 2/20 0.52
ALDH1A1 P00352 4/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
PTPN1 P18031 2/20 0.45
MEN1 O00255 1/20 0.45
LMNA P02545 1/20 0.45
MAPK1 P28482 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MAOB P27338 1/20 0.45
NPC1 O15118 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
GLA P06280 2/20 0.42
GAA P10253 2/20 0.42
GABRA1 P14867 1/20 0.41
GABRB2 P47870 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12413326 0.94 FPR1 (0.55) PPARGFPR1KDM4EMAPTALDH1A1
SCHEMBL2181840 0.93 PPARG (0.59) PPARGFPR1KDM4EMAPTALDH1A1
SCHEMBL13970374 0.90 PPARG (0.71) PPARGFPR1KDM4EMAPTALDH1A1
SCHEMBL2180371 0.86 KDM4E (0.60) PPARGFPR1KDM4EMAPTALDH1A1
SCHEMBL12413335 0.78 KDM4E (0.56) FPR1KDM4EMAPTALDH1A1SMN1; SMN2
SCHEMBL12413359 0.78 FPR1 (0.56) FPR1KDM4EMAPTALDH1A1SMN1; SMN2
SCHEMBL12413371 0.78 KDM4E (0.67) KDM4EMAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL2182484 0.76 PPARG (0.91) PPARGKDM4EMAPTALDH1A1PTPN1
SCHEMBL12413318 0.76 MAPT (0.53) FPR1KDM4EMAPTALDH1A1SMN1; SMN2
SCHEMBL6506553 0.75 MAPT (0.86) FPR1KDM4EMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166142-A1 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES NOVOGEN RESEARCH PTY LIMITED (AU) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166142-A1 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES NFE2L2, PTGS2, PTGES2 PPARG 135/4885FPR1 661/4885KDM4E 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.